| [1] | Bornkamp B, Bretz F, Dmitrienko A, Enas G, Gaydos B, et al. (2007) Innovative approaches for designing and analyzing adaptive dose-ranging trials. Journal of biopharmaceutical statistics 17: 965–995.
|
| [2] | Chevret S, Wiley J (2006) Statistical methods for dose-finding experiments: John Wiley and Sons Limited.
|
| [3] | Ting N (2006) Dose finding in drug development:Springer.
|
| [4] | Thall PF, Cook JD (2004) Dose-finding based on efficacy–toxicity trade-offs. Biometrics 60: 684–693.
|
| [5] | Yin G, Li Y, Ji Y (2006) Bayesian dose-finding in Phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 62: 777–787.
|
| [6] | O’Quigley J, Hughes MD, Fenton T (2001) Dose-finding designs for HIV studies. Biometrics 57: 1018–1029.
|
| [7] | Thall PF, Russell KE (1998) A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54: 251–264.
|
| [8] | Zhang W, Sargent DJ, Mandrekar S (2006) An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine 25: 2365–2383.
|
| [9] | Braun TM (2002) The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 23: 240–256.
|
| [10] | Dragalin V, Fedorov V (2006) Adaptive designs for dose-finding based on efficacy–toxicity response. Journal of Statistical Planning and Inference 136: 1800–1823.
|
| [11] | Fedorov VV, Wu Y (2007) Dose finding designs for continuous responses and binary utility. Journal of biopharmaceutical statistics 17: 1085–1096.
|
| [12] | Fedorov V, Wu Y, Zhang R (2012) Optimal dose-finding designs with correlated continuous and discrete responses. Statistics in Medicine 31: 217–234.
|
| [13] | Dragalin V, Fedorov VV, Wu Y (2008) Two-stage design for dose-finding that accounts for both efficacy and safety. Statistics in Medicine 27: 5156–5176.
|
| [14] | TAO A (2010) A dose finding method in joint modeling of efficacy and safety : Rutgers, The State University of New Jersey.
|
| [15] | O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46: 33–48.
|
| [16] | Ishizuka N, Ohashi Y (2001) The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Statistics in Medicine 20: 2661–2681.
|
| [17] | O’Quigley J, Conaway M (2010) Continual reassessment and related dose-finding designs.Statistical science: a review journal of the Institute of Mathematical Statistics. 25: 202–216.
|
| [18] | Lee SM, Cheng B, Cheung YK (2011) Continual reassessment method with multiple toxicity constraints. Biostatistics 12: 386–398.
|
| [19] | Fréchet M (1951) Sur les tableaux de corrélation dont les marges sont données. Annales de I’Université de Lyon.Section A: Sciences mathématiques et astronomie 9: 53–77.
|
| [20] | Sklar A (1959) Fonctions de répartition à n dimensions et leurs marges.Publications de l’Institut de Statistique de l’Université de Paris. 8: 229–231.
|
| [21] | Ruberg SJ (1995) Dose response studies I. Some design considerations. Journal of Biopharmaceutical Statisties 5: 1–14.
|
| [22] | Nebiyou Bekele B, Shen Y (2005) A bayesian approach to jointly modeling toxicity and biomarker expression in a Phase I/II dose-finding trial. Biometrics 61: 343–354.
|
| [23] | Manner H (2007) Estimation and model selection of copulas with an application to exchange rates: Maastricht Research School of Economics of Technology and Organizations.
|
